Pages that link to "Q45878107"

The following pages link to The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. (Q45878107):

Displaying 45 items.

• New developments in the management of moderate-to-severe hemophilia B (Q26751323) (← links)
• Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database (Q30655343) (← links)
• Treatment of hemophilia B: focus on recombinant factor IX. (Q34329068) (← links)
• Advances in haematological pharmacotherapy in 21st century (Q34406838) (← links)
• Coagulation factor concentrates: past, present, and future. (Q34659834) (← links)
• Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency (Q35006603) (← links)
• Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. (Q35692016) (← links)
• Design and characterization of an APC-specific serpin for the treatment of hemophilia. (Q36176667) (← links)
• Haemophilia B: Christmas disease (Q36221979) (← links)
• The promise and challenges of bioengineered recombinant clotting factors (Q36230850) (← links)
• Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia (Q36291059) (← links)
• The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. (Q36480548) (← links)
• Blood safety and the choice of anti-hemophilic factor concentrate (Q36488803) (← links)
• Recombinant plasma proteins (Q37822845) (← links)
• Current Options and New Developments in the Treatment of Haemophilia (Q37841547) (← links)
• Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies. (Q37976470) (← links)
• Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. (Q37984127) (← links)
• Haemophilia B: current pharmacotherapy and future directions (Q38040458) (← links)
• Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy (Q38115812) (← links)
• The role of Rixubis™ in the treatment of hemophilia B. (Q38210808) (← links)
• Emerging drugs for hemophilia B. (Q38237476) (← links)
• Current management of hemophilia B: recommendations, complications and emerging issues (Q38238972) (← links)
• Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices (Q38650475) (← links)
• Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes (Q38912064) (← links)
• Measurement properties of the Haem-A-QoL in haemophilia clinical trials (Q39062772) (← links)
• Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. (Q39499567) (← links)
• Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B. (Q39647561) (← links)
• Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. (Q42285404) (← links)
• A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use. (Q42623251) (← links)
• Haemophilia in the first years of life (Q44263772) (← links)
• Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization (Q45838031) (← links)
• An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B. (Q45855778) (← links)
• Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B. (Q45856730) (← links)
• Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants (Q45858842) (← links)
• Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects (Q45861492) (← links)
• A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa (Q45866041) (← links)
• Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. (Q45868033) (← links)
• Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial (Q45871094) (← links)
• Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa (Q45874429) (← links)
• Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey (Q45878819) (← links)
• RETRACTED: Pilot production of recombinant human clotting factor IX from transgenic sow milk (Q45879062) (← links)
• Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B. (Q45880341) (← links)
• Haemophilia in a real-world setting: the value of clinical experience in data collection (Q45882636) (← links)
• Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage (Q46868201) (← links)
• Haemophilia B: impact on patients and economic burden of disease (Q64041202) (← links)